| Mar'20 | Mar'19 | Mar'18 | Mar'17 | |||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net Loss | ||||||
-289,000 | -273,551 | -143,255 | -83,440 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Share-based compensation | ||||||
40,251 | 18,696 | 11,583 | 8,717 | |||
Depreciation and amortization | ||||||
1,765 | 438 | 243 | 61 | |||
Amortization of debt discount and issuance costs | ||||||
1,486 | 2,084 | 662 | 0 | |||
Gain (Loss) on Extinguishment of Debt | ||||||
-4,900 | 0 | 0 | - | |||
Acquisition of in-process research and development | ||||||
- | - | - | 13,117 | |||
Changes in the fair value of the Takeda warrant liability | ||||||
- | - | - | 27,518 | |||
Other items | ||||||
1,980 | -1,235 | 116 | -140 | |||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
-1,925 | 5,055 | 1,918 | 3,221 | |||
Deferred tax assets | ||||||
0 | 0 | -208 | 208 | |||
Income tax receivable | ||||||
524 | 476 | -895 | -105 | |||
Other assets | ||||||
10 | -76 | 3,065 | 0 | |||
Accounts payable | ||||||
4,315 | 6,441 | 1,249 | 3,329 | |||
Interest payable | ||||||
-1,077 | 795 | 282 | 0 | |||
Interest payable (related party) | ||||||
15 | 0 | 0 | - | |||
Accrued expenses | ||||||
-24,554 | 23,349 | 18,287 | 11,755 | |||
Operating lease liabilities | ||||||
-882 | - | - | - | |||
Deferred revenue | ||||||
40,000 | 0 | 0 | - | |||
Due to former majority shareholder | ||||||
-121 | -1,839 | -1,070 | 4,009 | |||
Deferred interest payable | ||||||
-2,273 | 2,018 | 255 | 0 | |||
Other | ||||||
3,582 | 0 | 0 | - | |||
Net Cash Provided by (Used in) Operating Activities | ||||||
-221,200 | -224,088 | -117,255 | -18,215 | |||
Cash flows from investing activities: | ||||||
Purchases of marketable securities | ||||||
32,076 | 0 | 0 | - | |||
Maturities of marketable securities | ||||||
29,240 | 0 | 0 | - | |||
Purchases of property and equipment | ||||||
1,099 | 1,236 | 604 | 967 | |||
Net cash used in investing activities | ||||||
-3,935 | -1,236 | -604 | -967 | |||
Cash flows from financing activities: | ||||||
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount | ||||||
- | - | - | 202,275 | |||
Initial public offering costs paid | ||||||
- | - | - | 2,311 | |||
Proceeds from issuance of common shares, net of issuance costs paid | ||||||
- | - | - | 0 | |||
Proceeds from Related Party Debt | ||||||
113,700 | 0 | 0 | - | |||
Proceeds from third party debt financing, net of financing costs paid | ||||||
0 | 53,974 | 43,751 | - | |||
Proceeds from stock option exercises | ||||||
942 | 1,300 | 36 | 0 | |||
Cash proceeds from debt financings, net of financing costs paid | ||||||
- | - | - | 0 | |||
Cash capital contribution from RSL | ||||||
- | - | - | 1,035 | |||
Settlement of former majority shareholder common shares subscribed | ||||||
0 | 0 | 1 | 0 | |||
Payments on third party debt financings and redemption fees | ||||||
105,420 | 0 | 0 | - | |||
Payment of annual debt administration fee to NovaQuest | ||||||
300 | 300 | 0 | 0 | |||
Due to RSL and RSI for amounts paid on behalf of the Company | ||||||
- | - | - | 979 | |||
Net cash provided by financing activities | ||||||
145,926 | 273,899 | 45,645 | 200,020 | |||
Net change in cash, cash equivalents and restricted cash | ||||||
-79,181 | 48,575 | -72,214 | 180,838 | |||
Non-cash financing activities: | ||||||
Acquisition of in-process research and development | ||||||
- | - | - | 13,117 | |||
Warrants issued to Hercules | ||||||
0 | 0 | 789 | 0 | |||
Supplemental disclosure of cash paid: | ||||||
Income taxes | ||||||
38 | 0 | 900 | 240 | |||
Interest | ||||||
13,030 | 3,923 | 845 | 0 | |||
Interest (related party) | ||||||
1,426 | 0 | 0 | - | |||
Public Equity Offering | ||||||
Proceeds from issuance of common shares, net of issuance costs paid | ||||||
134,458 | 74,391 | 0 | 0 | |||